Avon’s FY 2016 Marked By ‘Success Stories,’ But Not Enough Of Them
This article was originally published in The Rose Sheet
Following steady improvements over the first three quarters of fiscal 2016, Avon ends the year on a sour note with a disappointing fourth quarter. However, the international direct seller exceeded its cost savings targets and is now embarking on the next phase of its transformation plan with greater focus on growth.
You may also be interested in...
Management projects a strong second half after Avon's first-quarter sales advanced 2%, reported, but dipped in constant currency. Analysts received the guidance guardedly, and a group of investors led by Barington Capital are unconvinced the firm can turn things around under current leadership.
Following Avon Products Inc.'s announcement last month that it will spin off its North American business, execs provide a strategy update for investors, including a $350m cost-savings plan.
Gwyneth Paltrow’s Goop, Inc. demonstrated to the National Advertising Division’s satisfaction that Madame Ovary is “a daily regimen formulated to support thyroid health and smoothing the menopausal transition by providing nutritional support for women who may experience mild hot flashes, mood shifts, and stress-related fatigue.” Other ingredient-specific claims came up short.